Ratings by Wolfe Research (Kalpit Patel)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/17/2026 | Verastem | VSTM | New Coverage | Outperform (N/A) |
7.32 (8.65) |
18.17% | Details | |
| 9/17/2026 | Taysha Gene Therapies | TSHA | New Coverage | Outperform (N/A) |
5.08 (3.62) |
-28.74% | Details | |
| 9/17/2026 | Zymeworks | ZYME | New Coverage | Outperform (N/A) |
26.24 (25.03) |
-4.61% | Details | |
| 8/24/2026 | Janux Therapeutics | JANX | Upgrade | Outperform (Peerperform) |
17.39 (16.51) |
-5.06% | Details | |
| 7/27/2026 | Corcept Therapeutics | CORT | Downgrade | Underperform (Peerperform) |
96.66 (110.16) |
13.97% | Details | |
| 6/8/2026 | Tango Therapeutics Inc. | TNGX | Upgrade | Outperform (Peerperform) |
20.22 (22.04) |
9% | Details | |
| 5/19/2026 | Tyra Biosciences | TYRA | New Coverage | Peerperform (N/A) |
35.66 (18.52) |
-48.07% | Details | |
| 5/19/2026 | Mirum Pharmaceuticals | MIRM | New Coverage | Outperform (N/A) |
95.49 (80.14) |
-16.07% | Details | |
| 5/19/2026 | CytomX Therapeutics | CTMX | New Coverage | Outperform (N/A) |
3.50 (2.28) |
-34.86% | Details | |
| 5/19/2026 | CG Oncology | CGON | New Coverage | Peerperform (N/A) |
62.93 (59.85) |
-4.89% | Details | |
| 4/6/2026 | Soleno Therapeutics Inc. | SLNO | Downgrade | Peerperform (Outperform) |
39.49 (53.01) |
34.24% | Details | |
| 4/1/2026 | ORIC Pharmaceuticals | ORIC | Maintain | Peerperform (N/A) |
|
Details | ||
| 3/26/2026 | BeOne Medicines | ONC | New Coverage | Outperform (N/A) |
283.45 (369.06) |
30.2% | Details | |
| 3/26/2026 | Krystal Biotech | KRYS | New Coverage | Peerperform (N/A) |
254.95 (316.58) |
24.17% | Details | |
| 3/26/2026 | Olema Pharmaceuticals | OLMA | New Coverage | Peerperform (N/A) |
14.17 (6.58) |
-53.56% | Details | |
| 3/26/2026 | Genmab A/S | GMAB | New Coverage | Outperform (N/A) |
26.11 (37.00) |
41.71% | Details | |
| 3/25/2026 | Corcept Therapeutics | CORT | Upgrade | Peerperform (Underperform) |
33.82 (96.66) |
185.81% | Details | |
| 3/12/2026 | Celcuity Inc | CELC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | ORIC Pharmaceuticals | ORIC | Maintain | Peerperform (N/A) |
|
Details | ||
| 3/2/2026 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | Soleno Therapeutics Inc. | SLNO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/31/2025 | Corcept Therapeutics | CORT | Downgrade | Underperform (Peerperform) |
70.19 (33.82) |
-51.82% | Details | |
| 11/18/2025 | Summit Therapeutics plc | SMMT | New Coverage | Peerperform (N/A) |
18.03 (14.63) |
-18.86% | Details | |
| 11/18/2025 | Tango Therapeutics Inc. | TNGX | New Coverage | Peerperform (N/A) |
8.17 (20.22) |
147.49% | Details | |
| 11/18/2025 | Janux Therapeutics | JANX | New Coverage | Peerperform (N/A) |
29.28 (17.39) |
-40.61% | Details | |
| 11/18/2025 | Scholar Rock | SRRK | New Coverage | Outperform (N/A) |
37.41 (39.90) |
6.66% | Details | |
| 11/18/2025 | Revolution | RVMD | New Coverage | Outperform (N/A) |
67.75 (177.96) |
162.67% | Details | |
| 11/18/2025 | Soleno Therapeutics Inc. | SLNO | New Coverage | Outperform (N/A) |
49.42 (53.01) |
7.26% | Details | |
| 11/18/2025 | Exelixis | EXEL | New Coverage | Peerperform (N/A) |
41.65 (62.23) |
49.41% | Details | |
| 11/18/2025 | ORIC Pharmaceuticals | ORIC | New Coverage | Peerperform (N/A) |
12.25 (12.35) |
0.82% | Details | |
| 11/18/2025 | Arcellx Inc. | ACLX | New Coverage | Peerperform (N/A) |
89.98 (115.07) |
27.88% | Details | |
| 11/18/2025 | Ascendis Pharma | ASND | New Coverage | Outperform (N/A) |
204.40 (225.25) |
10.2% | Details | |
| 11/18/2025 | Corcept Therapeutics | CORT | New Coverage | Peerperform (N/A) |
75.54 (70.19) |
-7.08% | Details | |
| 11/18/2025 | Celcuity Inc | CELC | New Coverage | Outperform (N/A) |
92.68 (56.58) |
-38.95% | Details |
